The Primary Phase of Infection by Pathogenic Simian-Human Immunodeficiency Virus Results in Disruption of the Blood-Brain Barrier

AIDS Research and Human Retroviruses

Volumn 19, Issue 10, 2003, Pages 837-846

  Stephens, Edward B ^a   Singh, Dinesh K ^a   Kohler, M Eric ^a   Jackson, Mollie ^a   Pacyniak, Erik ^a   Berman, Nancy E J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; VIRUS RNA;

ANIMAL MODEL; ANIMAL TISSUE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MACACA; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; IMMUNOHISTOCHEMISTRY; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0242333219     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322493003     Document Type: Review

References (49)

1. Navia BA, Cho ES, Petito CK, and Price RW: The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986;19:525-535.
2. Spencer DC and Price RW: Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol 1992;46:655-693.
3. Tardieu M and Boutet A: HIV-1 and the central nervous system. Curr Top Microbiol Immunol 2002;265:183-195.
4. Sidtis JJ and Price RW: Early HIV-1 infection and the AIDS dementia complex. Neurology 1990;40:323-326.
5. Gray F, Scaravilli F, Everall I, Chretien F, An S, Boche D, Adle-Biassette H, Wingertsmann L, Durigon M, Hurtrel B, Chiodi F, Bell J, and Lantos P: Neuropathology of early HIV-1 infection. Brain Pathol 1996;6:1-15.
6. An SF and Scaravilli F: Early HIV-1 infection of the central nervous system. Arch Anat Cytol Pathol 1997;45:94-105.
7. Sharer LR, Baskin GB, Cho ES, Murphey-Corb M, Blumberg BM, and Epstein LG: Comparison of simian immunodeficiency virus and human immunodeficiency virus encephalitides in the immature host. Ann Neurol 1998;23:S108-S112.
8. Narayan O, Joag SV, and Stephens EB: Selected models of HIV-induced neurological disease. Curr Top Microbiol Immunol 1995;202:151-166.
9. Sasseville VG and Lackner AA: Neuropathogenesis of simian immunodeficiency virus infection in macaque monkeys. J Neurovirol 1997;3:1-9.
10. Mankowski JL, Flaherty MT, Spelman JP, Hauer DA, Didier PJ, Amedee AM, Murphey-Corb H, Kirstein LM, Munoz A, Clements JE, and Zink MC: Pathogenesis of simian immunodeficiency virus encephalitis: Viral determinants of neurovirulence. J Virol 1997;71:6055-6060.
11. Zink MC, Amedee AM, Mankowski JL, Craig L, Didier P, Carter DL, Munoz A, Murphey-Corb M, and Clements JE: Pathogenesis of SIV encephalitis-selection and replication of neurovirulent SIV. Am J Pathol 1997;151:793-803.
12. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M Jr, Spelman JP, Carter DL, Adams RJ, Lifson JD, and Clements JE: High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999;73:10480-10488.
13. Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, and Clements, JE: Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 2001;184:1015-1021.
14. Burudi EM and Fox HS: Simian immunodeficiency virus model of HIV-induced central nervous system dysfunction. Adv Virus Res 2001;56:435-468.
15. Chakrabarti L, Hurtrel M, Maire MA, Vazeux R, Dormont D, Montagnier L, and Hurtrel B: Early viral replication in the brain of SIV infected rhesus-monkeys. Am J Pathol 1991;139:1273-1280.
16. Raghavan R, Stephens EB, Joag SV, Adany I, Pinson DM, Li Z, Jia FL, Sahni M, Wang CY, Leung K, Foresman L, and Narayan O: Neuropathogenesis of chimeric simian human immunodeficiency virus infection in pig-tailed and rhesus macaques. Brain Pathol 1997;7:851-861.
17. KU-2 that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology 1999;260:295-307.
18. KU-1bMC33) with a truncated, non-membrane-bound vpu results in rapid CD4(+) T cell loss and neuroAIDS in pig-tailed macaques. Virology 2000;272:112-126.
19. Singh DK, McCormick C, Pacyniak E, Griffin D, Pinson DM, Sun F, Berman NEJ, and Stephens EB: Pathogenic and nef-interrupted simian-human immunodeficiency viruses traffic to the macaque CNS and cause astrocytosis early after inoculation. Virology 2002;296:39-51.
20. Petito CK and Cash KS: Blood-brain-barrier abnormalities in the acquired-immunodeficiency-syndrome - immunohistochemial localization of serum-proteins in postmortem brain. Ann Neurol 1992;32:658-666.
21. Gray F, Belec L, Chretien F, Dubreuil-Lemaire ML, Ricolfi F, Wingertsmann L, Poron, F, and Gherardi R: Acute, relapsing brain oedema with diffuse blood-brain barrier alteration and axonal damage in the acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol 1998;24:209-216.
22. Dallasta LM, Pisarov LA, Esplen JE, Werley JV, Moses AV, Nelson JA, and Achim CL: Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999;155:1915-1927.
23. Luabeya MK, Dallasta LM, Achim CL, Pauza CD, and Hamilton RL: Blood-brain barrier disruption in simian immunodeficiency virus encephalitis. Neuropathol Appl Neurobiol 2000;26:454-462.
24. KU-1bMC33) isolated from a macaque with NeuroAIDS has selected for mutations in Env and Nef that contributed to its pathogenic phenotype. Virology 2001;282:123-140.
25. Stephens EB, McCormick C, Pacyniak E, Griffin D, Pinson DM, Sun F, Nothnick W, Wong SW, Gunderson R, Berman NE, and Singh DK: Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 2002;293:252-261.
26. Stephens EB, Sahni M, Leung K, Raghavan R, Joag SV, and Narayan O: Nucleotide substitutions in the long terminal repeat (LTR) are not required for development of neurovirulence by simian immunodeficiency virus strain mac. J Gen Virol 1998; 79:1089-1100.
27. mac infection of Chinese and Indian rhesus macaques: Effects of splenectomy on virus burden. Virology 1994; 200:436-446.
28. Regier DA and Desrosiers RC: The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:1221-1231.
29. Stephens EB, Tian C, Dalton SB, and Gattone VH: Simian-human immunodeficiency-associated nephropathy in macaques. AIDS Res Hum Retroviruses 2000;16:1295-1306.
30. Paxinos G, Huang X-F, and Toga AW: The Rhesus Monkey Brain in Stereotactic Coordinates. Academic Press, New York, 2000.
31. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, and Wiley CA: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992;42:1736-1739.
32. Lackner AA, Smith MO, Munn RJ, Martfeld DJ, Gardner MB, Marx PA, and Dandekar S: Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am J Pathol 1991;139:609-621.
33. Smith MO, Heyes MP, and Lackner AA: Early intrathecal events in rhesus macaques (Macaca mulatta) infected with pathogenic or nonpathogenic molecular clones of simian immunodeficiency virus. Lab Invest 1995;72:547-558.
34. Watson PM, Anderson JM, Vanltallie CM, and Doctrow SR: The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 1991;129:6-10.
35. Kniesel U and Wolburg H: Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000;20:57-76.
36. Rizzardi GP, Barcellini W, Tambussi G, Lillo F, Malnati M, Perrin L, and Lazzarin, A: Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: Correlation with HIV-1 RNA and the clinical outcome. AIDS 1996;10:F45-F50.
37. Barcellini W, Rizzardi GP, Poli G, Tambussi G, Velati C, Meroni PL, Dalgleish AG, and Lazzarin A: Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:325-331.
38. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, Saag MS, Shaw GM, Quinn TC, Cohen OJ, Welbon CC, Pantaleo G, and Fauci AS: Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1996;93:4386-4391.
39. Fiala M, Looney DJ, Stins M, Way DD, Zhang L, Gan XH, Chiappelli F, Schweitzer ES, Shapshak P, Weinand M, Graves MC, Witte M, and Kim KS: TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med 1997;3:553-564.
40. Tsao N, Hsu HP, and Lei HY: TNF alpha-induced cyclooxygenase 2 not only increases the vasopermeability of blood-brain barrier but also enhances the neutrophil survival in Escherichia coli-induced brain inflammation. Prostaglandins Other Lipid Mediat 1999;57: 371-382.
41. Tsao N, Hsu HP, Wu CM, Liu CC, and Lei HY: Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. J Med Microbiol 2001;50:812-821.
42. Eisenhauer PB, Chaturvedi P, Fine RE, Ritchie AJ, Pober JS, Cleary TG, and Newburg DS: Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun 2001;69:1889-1894.
43. Mayne M, Bratanich AC, Chen P, Rana F, Nath A, and Power C: HIV-1 Tat molecular diversity and induction of TNF-alpha: Implications for HIV-induced neurological disease. Neuroimmunomodulation 1998;5:184-192.
44. Hofman FM, Dohadwala MM, Wright AD, Hinton DR, and Walker SM: Exogenous tat protein activates central nervous system-derived endothelial cells. J Neuroimmunol 1994;54:19-28.
45. Rappaport J, Joseph J, Croul S, Alexander G, Del Valle L, Amini S, and Khalili, K: Molecular pathway involved in HIV-1-induced CNS pathology: Role of viral regulatory protein, Tat. J Leukocyte Biol 1999;65:458-465.
46. Weiss JM, Nath A, Major EO, and Berman JW: HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and upregulates CCRS expression on human monocytes. J Immunol 1999;163:2953-2959.
47. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, and Berman JW: Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000;6: S82-S85.
48. Fox HS, Weed MR, Huitron-Resendiz S, Baig J, Horn TF, Dailey PJ, Bischofberger N, and Henriksen SJ: Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected moneky. J Clin Invest 2000;106:37-45.
49. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, Transidico P, Vagani A, Sozzani S, Mantovani A, Lazzarin A, and Poli G: Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998;12:1327-1332.